KYNBKyntra BioFinished
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer
Pancreatic Cancer Non-resectable
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 284 (final count)
- Started
- May 10, 2019
- Main results expected
- Jun 11, 2024
- Fully finished
- Jun 11, 2024
- Results posted
- Nov 5, 2024
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival
Measured over: Up to approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03941093 · record last updated 2024-11-05 · checked 2026-11-09 15:47 UTC